Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase III extension study of eculizumab in refractory generalized myasthenia gravis
NL-OMON41966Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of eculizumab in generalized myasthenia gravis (gMG) (2 arms), sponsored by Alexion Pharmaceuticals. Started Oct 2015; status: active, not recruiting.
02
Drugs
eculizumab
03
Conditions
generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on NL-OMON41966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41966.